中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2011年
2期
284-285
,共2页
膀胱移行细胞癌%E-CD%p16
膀胱移行細胞癌%E-CD%p16
방광이행세포암%E-CD%p16
Transitional cell carcinoma of bladder%E-CD%p16
目的 探讨E-CD和p16在人膀胱移行细胞癌中的表达及其意义.方法 采用免疫组织化学方法检测50例膀胱移行细胞癌和10例正常膀胱组织中的E-CD和p16蛋白的表达.结果 E-CD和p16在膀胱癌中阳性表达率分别为44.0%及54.0%.病理分级:E-CD在Ⅰ、Ⅱ、Ⅲ级膀胱癌中阳性表达率分别为68.7%、57.7%、25.0%,p16为75.0%、53.8%、12.5%,差异均有统计学意义(P＜0.05);肿瘤侵袭程度:E-CD及p16在非浸润型膀胱癌中阳性表达率分别为72.7%和68.2%,在浸润型膀胱癌中为42.9%和42.8%,均有不同程度的降低;肿瘤转移:E-CD与p16在无淋巴结转移组阳性表达率为69.4%与63.9%,在淋巴结转移组分别降低至21.4%与28.6%,差异有统计学意义(P＜0.05).结论 E-CD和p16均在膀胱移行细胞癌的发生发展过程中起重要作用,且可能与肿瘤的恶性程度及预后有关.
目的 探討E-CD和p16在人膀胱移行細胞癌中的錶達及其意義.方法 採用免疫組織化學方法檢測50例膀胱移行細胞癌和10例正常膀胱組織中的E-CD和p16蛋白的錶達.結果 E-CD和p16在膀胱癌中暘性錶達率分彆為44.0%及54.0%.病理分級:E-CD在Ⅰ、Ⅱ、Ⅲ級膀胱癌中暘性錶達率分彆為68.7%、57.7%、25.0%,p16為75.0%、53.8%、12.5%,差異均有統計學意義(P＜0.05);腫瘤侵襲程度:E-CD及p16在非浸潤型膀胱癌中暘性錶達率分彆為72.7%和68.2%,在浸潤型膀胱癌中為42.9%和42.8%,均有不同程度的降低;腫瘤轉移:E-CD與p16在無淋巴結轉移組暘性錶達率為69.4%與63.9%,在淋巴結轉移組分彆降低至21.4%與28.6%,差異有統計學意義(P＜0.05).結論 E-CD和p16均在膀胱移行細胞癌的髮生髮展過程中起重要作用,且可能與腫瘤的噁性程度及預後有關.
목적 탐토E-CD화p16재인방광이행세포암중적표체급기의의.방법 채용면역조직화학방법검측50례방광이행세포암화10례정상방광조직중적E-CD화p16단백적표체.결과 E-CD화p16재방광암중양성표체솔분별위44.0%급54.0%.병리분급:E-CD재Ⅰ、Ⅱ、Ⅲ급방광암중양성표체솔분별위68.7%、57.7%、25.0%,p16위75.0%、53.8%、12.5%,차이균유통계학의의(P＜0.05);종류침습정도:E-CD급p16재비침윤형방광암중양성표체솔분별위72.7%화68.2%,재침윤형방광암중위42.9%화42.8%,균유불동정도적강저;종류전이:E-CD여p16재무림파결전이조양성표체솔위69.4%여63.9%,재림파결전이조분별강저지21.4%여28.6%,차이유통계학의의(P＜0.05).결론 E-CD화p16균재방광이행세포암적발생발전과정중기중요작용,차가능여종류적악성정도급예후유관.
Objective To investigate the expression of E-CD and p16 in transitional cell carcinoma (TCC) of bladder and the implication. Methods The expression of E-CD and p16 was detected in 50cases of TCC and 10 cases of normal bladder tissue by immunohistochemical technique. Results The positive expression rate of E-CD and p16 in nomal bladder tissue ( 100% ) was significantly higher than that in the TCC (44. 0% and 54. 0% ). The positive expression rate of E-CD in the TCC of grades Ⅰ , Ⅱ, Ⅲ was 68.7%, 57.7% and 25.0%, and that of p16 was 75.0%, 53. 8%, 12. 5%, respectively. The positive expression rate of E-CD and p16 in non-muscle invasive TCC (Tis-T1) was 72.7% and 68. 2%, and that in muscle invasive TCC was 42. 9% and 42. 8% respectively. The positive expression rate of E-CD and p16 in no-lymphatic metastasis was 69. 4% and 63.9%, and that in lympathic metastasis was significantly reduced to 21.4% and 28. 6%. Conclusion E-CD and p16 play an important role in the pathogenesis and development of the TCC and they are helpful to predicting the prognosis of the patients with TCC.
